Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934)

References

• Sakurai T. The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness. Nat Rev Neurosci. 2007;8(3):171–181.
   PubMed Web of Science ®Google Scholar
• Gatfield J, Brisbare-Roch C, Jenck F, et al. Orexin receptor antagonists: a new concept in CNS disorders? Chem Med Chem. 2010;5(8):1197–1214.
   Web of Science ®Google Scholar
• Boss C, Roch C. Recent trends in orexin research–2010 to 2015. Bioorg Med Chem Lett. 2015;25(15):2875–2887.
   PubMed Web of Science ®Google Scholar
• Boss C. Orexin receptor antagonists–a patent review (2010 to August 2014). Expert Opin Ther Pat. 2014;24(12):1367–1381.
   PubMed Web of Science ®Google Scholar
• Lebold TP, Bonaventure P, Shireman BT. Selective orexin receptor antagonists. Bioorg Med Chem Lett. 2013;23(17):4761–4769.
   PubMed Web of Science ®Google Scholar
• Scammell TE, Saper CB. Orexin, drugs and motivated behaviors. Nat Neurosci. 2005;8(10):1286–1288.
   PubMed Web of Science ®Google Scholar
• Sakurai T. Roles of orexins and orexin receptors in central regulation of feeding behavior and energy homeostasis. CNS Neurol Disord Drug Targets. 2006;5(3):313–325.
   PubMedGoogle Scholar
• Sifferlen T, Boller A, Chardonneau A, et al. Discovery of substituted lactams as novel dual orexin receptor antagonists. Synthesis, preliminary structure-activity relationship studies and efforts towards improved metabolic stability and pharmacokinetic properties. Part 1. Bioorg Med Chem Lett. 2014;24(4):1201–1208.
   PubMed Web of Science ®Google Scholar
• Christopher JA. Small-molecule antagonists of the orexin receptors. Pharm Pat Anal. 2014;3(6):625–638.
   PubMedGoogle Scholar
• Christopher JA. Orexin receptor antagonists. Pharm Pat Anal. 2012;1(3):329–346.
   PubMedGoogle Scholar
• Roecker AJ, Cox CD, Coleman PJ. Orexin Receptor Antagonists: new therapeutic agents for the treatment of insomnia. J Med Chem. 2015. DOI:10.1021/acs.jmedchem.5b00832.
   PubMed Web of Science ®Google Scholar
• Boss C, Roch-Brisbare C, Steiner MA, et al. Structure-activity relationship, biological, and pharmacological characterization of the proline sulfonamide ACT-462206: a potent, brain-penetrant dual orexin 1/orexin 2 receptor antagonist. Chem Med Chem. 2014;9(11):2486–2496.
   Web of Science ®Google Scholar
• Cox CD, Breslin MJ, Whitman DB, et al. Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H −1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia. J Med Chem. 2010;53(14):5320–5332.
   PubMed Web of Science ®Google Scholar
• Brisbare-Roch C, Dingemanse J, Koberstein R, et al. Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nat Med. 2007;13(2):150–155.
   PubMed Web of Science ®Google Scholar
• Yoshida Y, Naoe Y, Terauchi T, et al. Discovery of (1R,2S)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-2-(3-fluorophenyl)-N-(5-fluor opyridin-2-yl)cyclopropanecarboxamide (E2006): A Potent and Efficacious Oral Orexin Receptor Antagonist. J Med Chem. 2015;58(11):4648–4664.
   PubMed Web of Science ®Google Scholar
• Letavic MA, Bonaventure P, Carruthers NI, et al. Novel Octahydropyrrolo[3,4-c]pyrroles Are Selective Orexin-2 Antagonists: SAR Leading to a Clinical Candidate. J Med Chem. 2015;58(14):5620–5636.
   PubMed Web of Science ®Google Scholar
• Bonaventure P, Shelton J, Yun S, et al. Characterization of JNJ-42847922, a Selective Orexin-2 Receptor Antagonist, as a Clinical Candidate for the Treatment of Insomnia. J Pharmacol Exp Ther. 2015;354(3):471–482.
   PubMed Web of Science ®Google Scholar
• Bonaventure P, Yun S, Johnson PL, et al. A selective orexin-1 receptor antagonist attenuates stress-induced hyperarousal without hypnotic effects. J Pharmacol Exp Ther. 2015;352(3):590–601.
   PubMed Web of Science ®Google Scholar
• Steiner MA, Gatfield J, Brisbare-Roch C, et al. Discovery and characterization of ACT-335827, an orally available, brain penetrant orexin receptor type 1 selective antagonist. Chem Med Chem. 2013;8(6):898–903.
   Web of Science ®Google Scholar
• Website Heptares: pipeline [Internet]. Heptares [ cited 2015 Nov 06]. Available from: http://www.heptares.com/pipeline/.
   Google Scholar
• Fieldhouse C, Glen A, Robinson JS, et al. Cyclopentylbenzamide derivatives and their use for the treatment of psychotic and cognitive disorders. WO2015/055994. 2015.
   Google Scholar
• Fieldhouse C, Glen A, Maine S, et al. 1,2-Substituted cyclopentanes as orexin receptor antagonists. WO2015/124932. 2015.
   Google Scholar
• Fieldhouse C, Glen A, Robinson JS, et al. Substituted cyclopentanes, tetrahydrofuranes and pyrrolidines as orexin receptor antagonists. WO2015/124934. 2015.
   Google Scholar
• Boss C, Brisbare-Roch C, Jenck F. Biomedical application of orexin/hypocretin receptor ligands in neuroscience. J Med Chem. 2009;52(4):891–903.
   PubMed Web of Science ®Google Scholar
• Coleman PJ, Renger JJ. Orexin receptor antagonists: a review of promising compounds patented since 2006. Expert Opin Ther Pat. 2010;20(3):307–324.
   PubMed Web of Science ®Google Scholar
• Kuduk SD, Skudlarek JW. 2-Amino-3-ester-pyridyl orexin receptor antagonists. WO2015/095441. 2015.
   Google Scholar
• Gelin CF, Lebold TP, Shireman BT, et al. Substituted 2-azabicycles and their use as orexin receptor modulators. WO2014/165070. 2014.
   Google Scholar
• Boss C, Brotschi C, Heidmann B, et al. 3,8-Diaza-bicyclo[4.2.0]oct-8-yl amides. WO2012/085852. 2012.
   Google Scholar
• Smith MI, Piper DC, Duxon MS, et al. Evidence implicating a role for orexin-1 receptor modulation of paradoxical sleep in the rat. Neurosci Lett. 2003;341(3):256–258.
   PubMed Web of Science ®Google Scholar
• Dugovic C, Shelton JE, Aluisio LE, et al. Blockade of orexin-1 receptors attenuates orexin-2 receptor antagonism-induced sleep promotion in the rat. J Pharmacol Exp Ther. 2009;330(1):142–151.
   PubMed Web of Science ®Google Scholar
• Morairty SR, Revel FG, Malherbe P, et al. Dual hypocretin receptor antagonism is more effective for sleep promotion than antagonism of either receptor alone. PLoS One. 2012;7(7):e39131.
   PubMed Web of Science ®Google Scholar
• Johnson PL, Federici LM, Fitz SD, et al. Orexin 1 and 2 Receptor Involvement in Co2 -Induced Panic-Associated Behavior and Autonomic Responses. Depress Anxiety. 2015;32(9):671–683.
   PubMed Web of Science ®Google Scholar
• Steiner MA, Sciarretta C, Pasquali A, et al. The selective orexin receptor 1 antagonist ACT-335827 in a rat model of diet-induced obesity associated with metabolic syndrome. Front Pharmacol. 2013;4:165.
   PubMed Web of Science ®Google Scholar
• Kang JE, Lim MM, Bateman RJ, et al. Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science. 2009;326(5955):1005–1007.
   PubMed Web of Science ®Google Scholar
• Website PR Newswire: Browse News Releases [Internet]. Eolas Therapeutics and AstraZeneca Partner to Develop Orexin-1 Receptor Antagonist for Multiple Indications [ cited 2015 Nov 06]. Available from: http://www.prnewswire.com/news-releases/eolas-therapeutics-and-astrazeneca-partner-to-develop-orexin-1-receptor-antagonist-for-multiple-indications-300106505.html/.
   Google Scholar